IQVIA Holdings Inc.

LSE:0JDM Stock Report

Market Cap: US$35.8b

IQVIA Holdings Valuation

Is 0JDM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JDM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0JDM ($197.75) is trading below our estimate of fair value ($363.57)

Significantly Below Fair Value: 0JDM is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JDM?

Key metric: As 0JDM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0JDM. This is calculated by dividing 0JDM's market cap by their current earnings.
What is 0JDM's PE Ratio?
PE Ratio25.5x
EarningsUS$1.41b
Market CapUS$35.83b

Price to Earnings Ratio vs Peers

How does 0JDM's PE Ratio compare to its peers?

The above table shows the PE ratio for 0JDM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.5x
ERGO Ergomed
46.7x14.2%UK£701.1m
GSK GSK
21.8x19.3%UK£54.7b
HVO hVIVO
7.4x-29.6%UK£130.0m
A Agilent Technologies
30.1x8.1%US$38.8b
0JDM IQVIA Holdings
25.5x13.7%US$35.8b

Price-To-Earnings vs Peers: 0JDM is expensive based on its Price-To-Earnings Ratio (25.5x) compared to the peer average (19.8x).

Price to Earnings Ratio vs Industry

How does 0JDM's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0JDM 25.5xIndustry Avg. 39.0xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0JDM is good value based on its Price-To-Earnings Ratio (25.5x) compared to the European Life Sciences industry average (39x).

Price to Earnings Ratio vs Fair Ratio

What is 0JDM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JDM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.5x
Fair PE Ratio31x

Price-To-Earnings vs Fair Ratio: 0JDM is good value based on its Price-To-Earnings Ratio (25.5x) compared to the estimated Fair Price-To-Earnings Ratio (31x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0JDM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$197.75
US$249.54
+26.2%
7.4%US$273.00US$200.00n/a24
Dec ’25US$200.84
US$252.18
+25.6%
8.2%US$290.00US$195.00n/a23
Nov ’25US$208.45
US$257.40
+23.5%
8.0%US$290.00US$195.00n/a23
Oct ’25US$232.87
US$275.56
+18.3%
6.1%US$312.00US$242.00n/a22
Sep ’25US$248.13
US$276.61
+11.5%
6.1%US$312.00US$242.00n/a20
Aug ’25US$247.63
US$275.21
+11.1%
6.2%US$312.00US$242.00n/a20
Jul ’25US$208.53
US$270.55
+29.7%
5.6%US$295.00US$241.00n/a20
Jun ’25US$218.57
US$271.44
+24.2%
5.5%US$295.00US$245.00n/a18
May ’25US$231.84
US$275.38
+18.8%
5.4%US$300.00US$250.00n/a19
Apr ’25US$252.54
US$273.70
+8.4%
5.7%US$300.00US$250.00n/a19
Mar ’25US$250.77
US$273.70
+9.1%
5.7%US$300.00US$250.00n/a19
Feb ’25US$210.01
US$246.33
+17.3%
6.7%US$286.00US$220.00n/a18
Jan ’25US$230.24
US$236.47
+2.7%
7.4%US$270.00US$200.00US$196.4219
Dec ’24US$216.66
US$229.52
+5.9%
8.4%US$258.90US$190.00US$200.8419
Nov ’24US$178.53
US$242.79
+36.0%
7.3%US$265.00US$210.00US$208.4519
Oct ’24US$199.71
US$252.16
+26.3%
5.7%US$281.00US$220.00US$232.8719
Sep ’24US$224.77
US$252.90
+12.5%
5.6%US$281.00US$220.00US$248.1320
Aug ’24US$220.68
US$252.34
+14.3%
8.0%US$285.00US$200.00US$247.6320
Jul ’24US$223.24
US$246.64
+10.5%
8.1%US$285.00US$200.00US$208.5320
Jun ’24US$198.98
US$245.64
+23.4%
8.2%US$285.00US$200.00US$218.5720
May ’24US$189.92
US$245.96
+29.5%
8.1%US$285.00US$200.00US$231.8421
Apr ’24US$197.14
US$258.58
+31.2%
4.6%US$285.00US$235.00US$252.5421
Mar ’24US$211.64
US$260.47
+23.1%
4.0%US$285.00US$235.00US$250.7719
Feb ’24US$230.77
US$256.58
+11.2%
5.1%US$285.00US$230.00US$210.0119
Jan ’24US$202.57
US$254.84
+25.8%
5.4%US$285.00US$230.00US$230.2419

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:29
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IQVIA Holdings Inc. is covered by 44 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Gregory BolanAvondale Partners
Eric ColdwellBaird